BioSpace News Archive

Crunch Franchise today announced the opening of a 24-hour gym with state-of-the-art equipment and amenities in Lawrence, Kansas. The expansive new club – located at 1900 W. 23rd Street – is expected to open in December 2018.

he upcoming winter season will feature unique El Niño conditions, according to DTN, a leading independent provider of insights and information.

People who use illicitly-made street opioids and test them for fentanyl by using fentanyl test strips (FTS) are five times more likely to engage in safer drug use behaviors when the test comes back positive, according to a new study by RTI International, a leading non-profit research institute, published today in the International Journal of Drug Policy.

Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced that the U.S. Food and Drug Administration (FDA) has approved NUZYRA™ (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI).

Today the National Safety Council made Arkansas the fifth stop on a nationwide tour of its exhibit, Prescribed to Death: A Memorial to the Victims of the Opioid Crisis, by unveiling the exhibit inside the Arkansas Union on the University of Arkansas campus.

Earlier this year, Bedfont, based in Harrietsham, announced that all its fundraising was going to its chosen charity of the year. In its latest charity efforts, Bedfont has organised a Big Row on October 11th; Bedfont’s Wellbeing Warriors will set up 2 rowing machines, kindly loaned by Aylesford Sports College, and 2 teams have accepted the challenge to row the length of the Channel, 21 miles, to raise money for Porchlight.

DaVita Inc.(NYSE: DVA), a health care services provider of kidney care, clinical research and care to the chronically ill, today acknowledged its collective achievements in improving clinical outcomes and research so far in 2018.

Sue MacLeman has commenced as Chair of MTPConnect, the Medical Technologies and Pharmaceuticals Industry Growth Centre.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced that the Company will host an Investor Day on Tuesday, October 23, 2018 from 12:00 p.m. to 2:00 p.m. in New York City.

Corvus Pharmaceuticals, Inc. today announced the publication of results of preclinical studies of CPI-444 demonstrating that it induces dose dependent anti-tumor responses as a monotherapy and in combination with anti-PD-1, anti-PD-L1 and anti-CTLA-4 therapies.